The management of secondary osteoporosis
- PMID: 16301195
- DOI: 10.1016/j.berh.2005.06.005
The management of secondary osteoporosis
Abstract
Secondary osteoporosis is common among patients being evaluated for osteoporosis. All men and premenopausal women with unexplained bone loss or a history of a fragility fracture should undergo a work-up for secondary osteoporosis. Also, postmenopausal women with risk factors for secondary osteoporosis should be carefully evaluated. The evaluation should include a thorough history, physical examination, bone mineral density testing, and laboratory testing. While there is no consensus for a cost-effective laboratory evaluation, some recommendations include: 25-hydroxyvitamin D, parathyroid hormone (PTH), serum and urine calcium, phosphate, creatinine, liver function tests, a complete blood count, testosterone in men, and thyroid-stimulating hormone. After a thorough review of the evaluation for secondary osteoporosis, this chapter reviews the pathophysiology and treatment of secondary osteoporotic disorders, including vitamin D insufficiency, osteomalacia, the osteoporosis of erosive inflammatory arthritis, ankylosing spondylitis, systemic lupus erythematosus, and osteoporosis related to anti-androgenic therapy for prostate cancer and aromatase inhibitor therapy for breast cancer. Physicians have a significant responsibility to evaluate and treat the underlying medical problem that is the cause of secondary osteoporosis and to optimize bone health in the individual patient.
Similar articles
-
[Postmenopausal osteoporosis: when is it necessary to perform laboratory testing? Which testing strategy?].Gynecol Obstet Fertil. 2008 Jun;36(6):656-8. doi: 10.1016/j.gyobfe.2008.04.005. Epub 2008 Jun 9. Gynecol Obstet Fertil. 2008. PMID: 18539507 Review. French.
-
Osteoporosis risk in premenopausal women.Pharmacotherapy. 2009 Mar;29(3):305-17. doi: 10.1592/phco.29.3.305. Pharmacotherapy. 2009. PMID: 19249949 Review.
-
Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.Maturitas. 2009 Sep 20;64(1):1-3. doi: 10.1016/j.maturitas.2009.07.012. Epub 2009 Aug 25. Maturitas. 2009. PMID: 19709824
-
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.Cancer Treat Rev. 2008;34 Suppl 1:S3-18. doi: 10.1016/j.ctrv.2008.03.007. Epub 2008 Jun 2. Cancer Treat Rev. 2008. PMID: 18515009
-
Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus.Nat Clin Pract Rheumatol. 2006 Oct;2(10):562-9. doi: 10.1038/ncprheum0298. Nat Clin Pract Rheumatol. 2006. PMID: 17016482 Review.
Cited by
-
Are Nonalcoholic Fatty Liver Disease and Bone Mineral Density Associated? - A Cross-Sectional Study Using Liver Biopsy and Dual-Energy X-Ray Absorptiometry.JBMR Plus. 2023 Jan 11;7(3):e10714. doi: 10.1002/jbm4.10714. eCollection 2023 Mar. JBMR Plus. 2023. PMID: 36936359 Free PMC article.
-
The value of laboratory tests in diagnosing secondary osteoporosis at a fracture and osteoporosis outpatient clinic.Geriatr Orthop Surg Rehabil. 2013 Jun;4(2):53-7. doi: 10.1177/2151458513501176. Geriatr Orthop Surg Rehabil. 2013. PMID: 24093077 Free PMC article.
-
Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.Osteoporos Int. 2013 Mar;24(3):941-7. doi: 10.1007/s00198-012-2097-4. Epub 2012 Aug 8. Osteoporos Int. 2013. PMID: 22872068
-
The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease.Wien Klin Wochenschr. 2012 Aug;124(15-16):526-31. doi: 10.1007/s00508-012-0211-4. Epub 2012 Aug 1. Wien Klin Wochenschr. 2012. PMID: 22850810
-
The association between hip fracture and hip osteoarthritis: a case-control study.BMC Musculoskelet Disord. 2010 Nov 26;11:274. doi: 10.1186/1471-2474-11-274. BMC Musculoskelet Disord. 2010. PMID: 21110879 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
